Skip to main content

FDA Approvals

Temodar Receives FDA Approval for New and Updated Indications and Doses Through the Project Renewal Program

Ojjaara FDA Approved for Treatment of Myelofibrosis and Anemia

Exxua, a First-in-Class Oral Selective 5-HT1A Receptor Agonist, FDA Approved for Major Depressive Disorder

FDA Approves Pombiliti Plus Opfolda for Treatment of Pompe Disease

Tofidence, First Biosimilar to Actemra, FDA Approved for Rheumatoid Arthritis and 2 Forms of Juvenile Idiopathic Arthritis

FDA Approved Rivfloza for Treatment of Primary Hyperoxaluria Type 1 in Children and Adults

Braftovi Plus Mektovi Now FDA Approved for Treatment of Metastatic Non–Small Cell Lung Cancer With BRAF Mutation

Opdivo Now Approved for Adjuvant Treatment of Stage IIB/C Melanoma

Keytruda Now Approved for Neoadjuvant and Adjuvant Treatment of Resectable Non–Small Cell Lung Cancer

IMJUDO (Tremelimumab-actl) in Combination With IMFINZI (Durvalumab) Receives FDA Approval for HCC and NSCLC

Jerm Day-Storms, PhD, MWC

Page 4 of 53
Results 31 - 40 of 527